News coverage about Davita (NYSE:DVA) has trended somewhat positive on Sunday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Davita earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.6616690301397 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news headlines that may have impacted Accern Sentiment’s rankings:

Shares of Davita (NYSE:DVA) traded down $0.19 during trading on Friday, hitting $73.65. 1,301,144 shares of the stock traded hands, compared to its average volume of 1,417,911. The company has a debt-to-equity ratio of 1.87, a current ratio of 2.88 and a quick ratio of 1.35. Davita has a 1 year low of $52.51 and a 1 year high of $80.71. The company has a market capitalization of $13,438.33, a PE ratio of 21.41, a price-to-earnings-growth ratio of 1.65 and a beta of 0.99.

Davita (NYSE:DVA) last issued its earnings results on Tuesday, February 13th. The company reported $0.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.02). Davita had a return on equity of 12.86% and a net margin of 4.65%. The firm had revenue of $2.78 billion during the quarter, compared to the consensus estimate of $3.90 billion. During the same quarter in the prior year, the business posted $0.98 EPS. analysts forecast that Davita will post 4.18 earnings per share for the current year.

Several research analysts have commented on the stock. Bank of America reissued a “buy” rating and set a $92.00 price target (up from $85.00) on shares of Davita in a research note on Thursday, January 11th. Wolfe Research raised shares of Davita from a “market perform” rating to an “outperform” rating in a research note on Monday, October 23rd. JPMorgan Chase & Co. lifted their price target on shares of Davita from $4.90 to $84.00 and gave the stock a “strong-buy” rating in a research note on Thursday, December 7th. SunTrust Banks restated a “hold” rating and issued a $80.00 target price on shares of Davita in a report on Wednesday. Finally, Robert W. Baird upgraded shares of Davita from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $63.00 to $82.00 in a report on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $79.30.

In related news, CEO Javier Rodriguez sold 22,532 shares of Davita stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $67.48, for a total value of $1,520,459.36. Following the sale, the chief executive officer now owns 210,317 shares in the company, valued at $14,192,191.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Charles Berg sold 7,048 shares of Davita stock in a transaction on Monday, December 11th. The shares were sold at an average price of $69.24, for a total transaction of $488,003.52. Following the completion of the sale, the insider now owns 5,359 shares in the company, valued at approximately $371,057.16. The disclosure for this sale can be found here. Insiders sold 121,509 shares of company stock worth $8,310,388 in the last 90 days. Company insiders own 2.10% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Davita (DVA) Receives Daily Media Sentiment Rating of 0.20” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at

About Davita

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Insider Buying and Selling by Quarter for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with's FREE daily email newsletter.